Matches in SemOpenAlex for { <https://semopenalex.org/work/W4212854039> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- W4212854039 endingPage "337" @default.
- W4212854039 startingPage "333" @default.
- W4212854039 abstract "ASCO 2001 was a banner year for innovative systemic therapy for sarcomas. Imatinib mesylate (STI571, Gleevec) shows clear activity not only in chronic myelogenous leukemia, for which the drug received Food and Drug Administration approval, but also in gastrointestinal stromal tumors as well, by virtue of imatinib mesylate binding to the abl, kit, and platelet-derived growth factor receptor tyrosine kinases. Ecteinascidin-743 (ET-743) demonstrates activity against a fraction of other soft-tissue sarcomas. Gemcitabine-based regimens show at least some activity against a subset of soft-tissue sarcomas. Given the lack of new agents for sarcoma therapy since the development of ifosfamide, these studies give hope that the term effective systemic therapy for sarcoma might become a reality." @default.
- W4212854039 created "2022-02-24" @default.
- W4212854039 creator A5068677359 @default.
- W4212854039 date "2001-08-01" @default.
- W4212854039 modified "2023-09-26" @default.
- W4212854039 title "Sarcoma" @default.
- W4212854039 cites W1856961639 @default.
- W4212854039 cites W1996252991 @default.
- W4212854039 cites W2099134833 @default.
- W4212854039 cites W2104953667 @default.
- W4212854039 cites W2138266786 @default.
- W4212854039 cites W2324850882 @default.
- W4212854039 doi "https://doi.org/10.1634/theoncologist.6-4-333" @default.
- W4212854039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11524551" @default.
- W4212854039 hasPublicationYear "2001" @default.
- W4212854039 type Work @default.
- W4212854039 citedByCount "3" @default.
- W4212854039 crossrefType "journal-article" @default.
- W4212854039 hasAuthorship W4212854039A5068677359 @default.
- W4212854039 hasBestOaLocation W42128540391 @default.
- W4212854039 hasConcept C142724271 @default.
- W4212854039 hasConcept C2778256501 @default.
- W4212854039 hasConcept C71924100 @default.
- W4212854039 hasConceptScore W4212854039C142724271 @default.
- W4212854039 hasConceptScore W4212854039C2778256501 @default.
- W4212854039 hasConceptScore W4212854039C71924100 @default.
- W4212854039 hasIssue "4" @default.
- W4212854039 hasLocation W42128540391 @default.
- W4212854039 hasLocation W42128540392 @default.
- W4212854039 hasOpenAccess W4212854039 @default.
- W4212854039 hasPrimaryLocation W42128540391 @default.
- W4212854039 hasRelatedWork W14536495 @default.
- W4212854039 hasRelatedWork W16679105 @default.
- W4212854039 hasRelatedWork W18212846 @default.
- W4212854039 hasRelatedWork W2422317 @default.
- W4212854039 hasRelatedWork W3553373 @default.
- W4212854039 hasRelatedWork W4105886 @default.
- W4212854039 hasRelatedWork W518170 @default.
- W4212854039 hasRelatedWork W5453825 @default.
- W4212854039 hasRelatedWork W5794328 @default.
- W4212854039 hasRelatedWork W7167528 @default.
- W4212854039 hasVolume "6" @default.
- W4212854039 isParatext "false" @default.
- W4212854039 isRetracted "false" @default.
- W4212854039 workType "article" @default.